What is the current valuation of the Compounded Pharmacy Market?

The market was valued at 16.6 USD Billion in 2024. Read More

What is the projected market size for the Compounded Pharmacy Market by 2035?

The market is projected to reach 34.95 USD Billion by 2035. Read More

What is the expected CAGR for the Compounded Pharmacy Market during the forecast period?

The expected CAGR for the market from 2025 to 2035 is 7.0%. Read More

Which therapeutic area is expected to show significant growth in the Compounded Pharmacy Market?

Pain Management and Hormonal Therapies are anticipated to show substantial growth, with valuations reaching 7.5 USD Billion and 8.5 USD Billion respectively by 2035. Read More

What are the leading formulation types in the Compounded Pharmacy Market?

Oral and Injectable formulations are projected to dominate, with expected valuations of 8.5 USD Billion and 6.5 USD Billion by 2035. Read More

Who are the key players in the Compounded Pharmacy Market?

Key players include Fagron, Patterson Companies, Wedgewood Pharmacy, and Compounding Pharmacy of America. Read More

What end-user segments are driving the Compounded Pharmacy Market?

Pharmacies and Hospitals are leading end-user segments, with projected valuations of 8.5 USD Billion and 7.5 USD Billion by 2035. Read More

What ingredient types are most utilized in compounded pharmaceuticals?

Active Pharmaceutical Ingredients and Excipients are the most utilized, with expected valuations of 12.5 USD Billion and 8.5 USD Billion by 2035. Read More

How does the Compounded Pharmacy Market compare across different therapeutic areas?

Therapeutic areas like Dermatology and Pediatric Care are also expected to grow, reaching 6.5 USD Billion and 5.5 USD Billion respectively by 2035. Read More

What trends are influencing the growth of the Compounded Pharmacy Market?

The increasing demand for personalized medicine and tailored therapies appears to be driving growth in the market. Read More

Compounded Pharmacy Market

ID: MRFR/HC/20515-HCR

128 Pages

Satyendra Maurya

Last Updated: June 08, 2026

Compounded Pharmacy Market Research Report By Therapeutic Area (Pain Management, Hormonal Therapies, Pediatric Care, Dermatology, Ophthalmology), By Formulation Type (Topical, Oral, Injectable, Nasal, Transdermal), By End User (Hospitals, Pharmacies, Home Healthcare, Long-Term Care Facilities, Research Laboratories), By Ingredient Type (Active Pharmaceutical Ingredients, Excipients, Preservatives, Flavoring Agents, Coloring Agents) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

Compounded Pharmacy Market

Market Size

Forecast Period2025 - 2035

CAGR (2025 - 2035)7.0%

2024 Market Size$ 16.6 Billion

2025 Market Size$ 17.76 Billion

2035 Market Size$ 34.95 Billion

Key Players

Companies such as Fagron

Patterson Companies

Wedgewood Pharmacy

Compounding Pharmacy of America

PharMEDium Services

Custom Meds

Trends

Personalized Medicine Demand
Technological Advancements
Regulatory Adaptations

Opportunities

Aging Population
Rising Prevalence of Chronic Diseases
Technological Innovations in Pharmacy

Summary Table of Contents Segmentation Methodology Download PDF

Certified Researchers

Customize Report

SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS |
1. 1.1 EXECUTIVE SUMMARY | |
  1. 1.1.1 Market Overview | |
  2. 1.1.2 Key Findings | |
  3. 1.1.3 Market Segmentation | |
  4. 1.1.4 Competitive Landscape | |
  5. 1.1.5 Challenges and Opportunities | |
  6. 1.1.6 Future Outlook 2
SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE |
1. 2.1 MARKET INTRODUCTION | |
  1. 2.1.1 Definition | |
  2. 2.1.2 Scope of the study | | |
    1. 2.1.2.1 Research Objective | | |
    2. 2.1.2.2 Assumption | | |
    3. 2.1.2.3 Limitations |
2. 2.2 RESEARCH METHODOLOGY | |
  1. 2.2.1 Overview | |
  2. 2.2.2 Data Mining | |
  3. 2.2.3 Secondary Research | |
  4. 2.2.4 Primary Research | | |
    1. 2.2.4.1 Primary Interviews and Information Gathering Process | | |
    2. 2.2.4.2 Breakdown of Primary Respondents | |
  5. 2.2.5 Forecasting Model | |
  6. 2.2.6 Market Size Estimation | | |
    1. 2.2.6.1 Bottom-Up Approach | | |
    2. 2.2.6.2 Top-Down Approach | |
  7. 2.2.7 Data Triangulation | |
  8. 2.2.8 Validation 3
SECTION III: QUALITATIVE ANALYSIS |
1. 3.1 MARKET DYNAMICS | |
  1. 3.1.1 Overview | |
  2. 3.1.2 Drivers | |
  3. 3.1.3 Restraints | |
  4. 3.1.4 Opportunities |
2. 3.2 MARKET FACTOR ANALYSIS | |
  1. 3.2.1 Value chain Analysis | |
  2. 3.2.2 Porter's Five Forces Analysis | | |
    1. 3.2.2.1 Bargaining Power of Suppliers | | |
    2. 3.2.2.2 Bargaining Power of Buyers | | |
    3. 3.2.2.3 Threat of New Entrants | | |
    4. 3.2.2.4 Threat of Substitutes | | |
    5. 3.2.2.5 Intensity of Rivalry | |
  3. 3.2.3 COVID-19 Impact Analysis | | |
    1. 3.2.3.1 Market Impact Analysis | | |
    2. 3.2.3.2 Regional Impact | | |
    3. 3.2.3.3 Opportunity and Threat Analysis 4
SECTION IV: QUANTITATIVE ANALYSIS |
1. 4.1 Healthcare, BY Therapeutic Area (USD Billion) | |
  1. 4.1.1 Pain Management | |
  2. 4.1.2 Hormonal Therapies | |
  3. 4.1.3 Pediatric Care | |
  4. 4.1.4 Dermatology | |
  5. 4.1.5 Ophthalmology |
2. 4.2 Healthcare, BY Formulation Type (USD Billion) | |
  1. 4.2.1 Topical | |
  2. 4.2.2 Oral | |
  3. 4.2.3 Injectable | |
  4. 4.2.4 Nasal | |
  5. 4.2.5 Transdermal |
3. 4.3 Healthcare, BY End User (USD Billion) | |
  1. 4.3.1 Hospitals | |
  2. 4.3.2 Pharmacies | |
  3. 4.3.3 Home Healthcare | |
  4. 4.3.4 Long-Term Care Facilities | |
  5. 4.3.5 Research Laboratories |
4. 4.4 Healthcare, BY Ingredient Type (USD Billion) | |
  1. 4.4.1 Active Pharmaceutical Ingredients | |
  2. 4.4.2 Excipients | |
  3. 4.4.3 Preservatives | |
  4. 4.4.4 Flavoring Agents | |
  5. 4.4.5 Coloring Agents |
5. 4.5 Healthcare, BY Region (USD Billion) | |
  1. 4.5.1 North America | | |
    1. 4.5.1.1 US | | |
    2. 4.5.1.2 Canada | |
  2. 4.5.2 Europe | | |
    1. 4.5.2.1 Germany | | |
    2. 4.5.2.2 UK | | |
    3. 4.5.2.3 France | | |
    4. 4.5.2.4 Russia | | |
    5. 4.5.2.5 Italy | | |
    6. 4.5.2.6 Spain | | |
    7. 4.5.2.7 Rest of Europe | |
  3. 4.5.3 APAC | | |
    1. 4.5.3.1 China | | |
    2. 4.5.3.2 India | | |
    3. 4.5.3.3 Japan | | |
    4. 4.5.3.4 South Korea | | |
    5. 4.5.3.5 Malaysia | | |
    6. 4.5.3.6 Thailand | | |
    7. 4.5.3.7 Indonesia | | |
    8. 4.5.3.8 Rest of APAC | |
  4. 4.5.4 South America | | |
    1. 4.5.4.1 Brazil | | |
    2. 4.5.4.2 Mexico | | |
    3. 4.5.4.3 Argentina | | |
    4. 4.5.4.4 Rest of South America | |
  5. 4.5.5 MEA | | |
    1. 4.5.5.1 GCC Countries | | |
    2. 4.5.5.2 South Africa | | |
    3. 4.5.5.3 Rest of MEA 5
SECTION V: COMPETITIVE ANALYSIS |
1. 5.1 Competitive Landscape | |
  1. 5.1.1 Overview | |
  2. 5.1.2 Competitive Analysis | |
  3. 5.1.3 Market share Analysis | |
  4. 5.1.4 Major Growth Strategy in the Healthcare | |
  5. 5.1.5 Competitive Benchmarking | |
  6. 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare | |
  7. 5.1.7 Key developments and growth strategies | | |
    1. 5.1.7.1 New Product Launch/Service Deployment | | |
    2. 5.1.7.2 Merger & Acquisitions | | |
    3. 5.1.7.3 Joint Ventures | |
  8. 5.1.8 Major Players Financial Matrix | | |
    1. 5.1.8.1 Sales and Operating Income | | |
    2. 5.1.8.2 Major Players R&D Expenditure. 2023 |
2. 5.2 Company Profiles | |
  1. 5.2.1 Fagron (NL) | | |
    1. 5.2.1.1 Financial Overview | | |
    2. 5.2.1.2 Products Offered | | |
    3. 5.2.1.3 Key Developments | | |
    4. 5.2.1.4 SWOT Analysis | | |
    5. 5.2.1.5 Key Strategies | |
  2. 5.2.2 Patterson Companies (US) | | |
    1. 5.2.2.1 Financial Overview | | |
    2. 5.2.2.2 Products Offered | | |
    3. 5.2.2.3 Key Developments | | |
    4. 5.2.2.4 SWOT Analysis | | |
    5. 5.2.2.5 Key Strategies | |
  3. 5.2.3 Wedgewood Pharmacy (US) | | |
    1. 5.2.3.1 Financial Overview | | |
    2. 5.2.3.2 Products Offered | | |
    3. 5.2.3.3 Key Developments | | |
    4. 5.2.3.4 SWOT Analysis | | |
    5. 5.2.3.5 Key Strategies | |
  4. 5.2.4 Compounding Pharmacy of America (US) | | |
    1. 5.2.4.1 Financial Overview | | |
    2. 5.2.4.2 Products Offered | | |
    3. 5.2.4.3 Key Developments | | |
    4. 5.2.4.4 SWOT Analysis | | |
    5. 5.2.4.5 Key Strategies | |
  5. 5.2.5 PharMEDium Services (US) | | |
    1. 5.2.5.1 Financial Overview | | |
    2. 5.2.5.2 Products Offered | | |
    3. 5.2.5.3 Key Developments | | |
    4. 5.2.5.4 SWOT Analysis | | |
    5. 5.2.5.5 Key Strategies | |
  6. 5.2.6 Custom Meds (US) | | |
    1. 5.2.6.1 Financial Overview | | |
    2. 5.2.6.2 Products Offered | | |
    3. 5.2.6.3 Key Developments | | |
    4. 5.2.6.4 SWOT Analysis | | |
    5. 5.2.6.5 Key Strategies | |
  7. 5.2.7 Northwest Pharmacy (US) | | |
    1. 5.2.7.1 Financial Overview | | |
    2. 5.2.7.2 Products Offered | | |
    3. 5.2.7.3 Key Developments | | |
    4. 5.2.7.4 SWOT Analysis | | |
    5. 5.2.7.5 Key Strategies | |
  8. 5.2.8 Bespoke Pharmacy (US) | | |
    1. 5.2.8.1 Financial Overview | | |
    2. 5.2.8.2 Products Offered | | |
    3. 5.2.8.3 Key Developments | | |
    4. 5.2.8.4 SWOT Analysis | | |
    5. 5.2.8.5 Key Strategies |
3. 5.3 Appendix | |
  1. 5.3.1 References | |
  2. 5.3.2 Related Reports 6 LIST OF FIGURES |
4. 6.1 MARKET SYNOPSIS |
5. 6.2 NORTH AMERICA MARKET ANALYSIS |
6. 6.3 US MARKET ANALYSIS BY THERAPEUTIC AREA |
7. 6.4 US MARKET ANALYSIS BY FORMULATION TYPE |
8. 6.5 US MARKET ANALYSIS BY END USER |
9. 6.6 US MARKET ANALYSIS BY INGREDIENT TYPE |
10. 6.7 CANADA MARKET ANALYSIS BY THERAPEUTIC AREA |
11. 6.8 CANADA MARKET ANALYSIS BY FORMULATION TYPE |
12. 6.9 CANADA MARKET ANALYSIS BY END USER |
13. 6.10 CANADA MARKET ANALYSIS BY INGREDIENT TYPE |
14. 6.11 EUROPE MARKET ANALYSIS |
15. 6.12 GERMANY MARKET ANALYSIS BY THERAPEUTIC AREA |
16. 6.13 GERMANY MARKET ANALYSIS BY FORMULATION TYPE |
17. 6.14 GERMANY MARKET ANALYSIS BY END USER |
18. 6.15 GERMANY MARKET ANALYSIS BY INGREDIENT TYPE |
19. 6.16 UK MARKET ANALYSIS BY THERAPEUTIC AREA |
20. 6.17 UK MARKET ANALYSIS BY FORMULATION TYPE |
21. 6.18 UK MARKET ANALYSIS BY END USER |
22. 6.19 UK MARKET ANALYSIS BY INGREDIENT TYPE |
23. 6.20 FRANCE MARKET ANALYSIS BY THERAPEUTIC AREA |
24. 6.21 FRANCE MARKET ANALYSIS BY FORMULATION TYPE |
25. 6.22 FRANCE MARKET ANALYSIS BY END USER |
26. 6.23 FRANCE MARKET ANALYSIS BY INGREDIENT TYPE |
27. 6.24 RUSSIA MARKET ANALYSIS BY THERAPEUTIC AREA |
28. 6.25 RUSSIA MARKET ANALYSIS BY FORMULATION TYPE |
29. 6.26 RUSSIA MARKET ANALYSIS BY END USER |
30. 6.27 RUSSIA MARKET ANALYSIS BY INGREDIENT TYPE |
31. 6.28 ITALY MARKET ANALYSIS BY THERAPEUTIC AREA |
32. 6.29 ITALY MARKET ANALYSIS BY FORMULATION TYPE |
33. 6.30 ITALY MARKET ANALYSIS BY END USER |
34. 6.31 ITALY MARKET ANALYSIS BY INGREDIENT TYPE |
35. 6.32 SPAIN MARKET ANALYSIS BY THERAPEUTIC AREA |
36. 6.33 SPAIN MARKET ANALYSIS BY FORMULATION TYPE |
37. 6.34 SPAIN MARKET ANALYSIS BY END USER |
38. 6.35 SPAIN MARKET ANALYSIS BY INGREDIENT TYPE |
39. 6.36 REST OF EUROPE MARKET ANALYSIS BY THERAPEUTIC AREA |
40. 6.37 REST OF EUROPE MARKET ANALYSIS BY FORMULATION TYPE |
41. 6.38 REST OF EUROPE MARKET ANALYSIS BY END USER |
42. 6.39 REST OF EUROPE MARKET ANALYSIS BY INGREDIENT TYPE |
43. 6.40 APAC MARKET ANALYSIS |
44. 6.41 CHINA MARKET ANALYSIS BY THERAPEUTIC AREA |
45. 6.42 CHINA MARKET ANALYSIS BY FORMULATION TYPE |
46. 6.43 CHINA MARKET ANALYSIS BY END USER |
47. 6.44 CHINA MARKET ANALYSIS BY INGREDIENT TYPE |
48. 6.45 INDIA MARKET ANALYSIS BY THERAPEUTIC AREA |
49. 6.46 INDIA MARKET ANALYSIS BY FORMULATION TYPE |
50. 6.47 INDIA MARKET ANALYSIS BY END USER |
51. 6.48 INDIA MARKET ANALYSIS BY INGREDIENT TYPE |
52. 6.49 JAPAN MARKET ANALYSIS BY THERAPEUTIC AREA |
53. 6.50 JAPAN MARKET ANALYSIS BY FORMULATION TYPE |
54. 6.51 JAPAN MARKET ANALYSIS BY END USER |
55. 6.52 JAPAN MARKET ANALYSIS BY INGREDIENT TYPE |
56. 6.53 SOUTH KOREA MARKET ANALYSIS BY THERAPEUTIC AREA |
57. 6.54 SOUTH KOREA MARKET ANALYSIS BY FORMULATION TYPE |
58. 6.55 SOUTH KOREA MARKET ANALYSIS BY END USER |
59. 6.56 SOUTH KOREA MARKET ANALYSIS BY INGREDIENT TYPE |
60. 6.57 MALAYSIA MARKET ANALYSIS BY THERAPEUTIC AREA |
61. 6.58 MALAYSIA MARKET ANALYSIS BY FORMULATION TYPE |
62. 6.59 MALAYSIA MARKET ANALYSIS BY END USER |
63. 6.60 MALAYSIA MARKET ANALYSIS BY INGREDIENT TYPE |
64. 6.61 THAILAND MARKET ANALYSIS BY THERAPEUTIC AREA |
65. 6.62 THAILAND MARKET ANALYSIS BY FORMULATION TYPE |
66. 6.63 THAILAND MARKET ANALYSIS BY END USER |
67. 6.64 THAILAND MARKET ANALYSIS BY INGREDIENT TYPE |
68. 6.65 INDONESIA MARKET ANALYSIS BY THERAPEUTIC AREA |
69. 6.66 INDONESIA MARKET ANALYSIS BY FORMULATION TYPE |
70. 6.67 INDONESIA MARKET ANALYSIS BY END USER |
71. 6.68 INDONESIA MARKET ANALYSIS BY INGREDIENT TYPE |
72. 6.69 REST OF APAC MARKET ANALYSIS BY THERAPEUTIC AREA |
73. 6.70 REST OF APAC MARKET ANALYSIS BY FORMULATION TYPE |
74. 6.71 REST OF APAC MARKET ANALYSIS BY END USER |
75. 6.72 REST OF APAC MARKET ANALYSIS BY INGREDIENT TYPE |
76. 6.73 SOUTH AMERICA MARKET ANALYSIS |
77. 6.74 BRAZIL MARKET ANALYSIS BY THERAPEUTIC AREA |
78. 6.75 BRAZIL MARKET ANALYSIS BY FORMULATION TYPE |
79. 6.76 BRAZIL MARKET ANALYSIS BY END USER |
80. 6.77 BRAZIL MARKET ANALYSIS BY INGREDIENT TYPE |
81. 6.78 MEXICO MARKET ANALYSIS BY THERAPEUTIC AREA |
82. 6.79 MEXICO MARKET ANALYSIS BY FORMULATION TYPE |
83. 6.80 MEXICO MARKET ANALYSIS BY END USER |
84. 6.81 MEXICO MARKET ANALYSIS BY INGREDIENT TYPE |
85. 6.82 ARGENTINA MARKET ANALYSIS BY THERAPEUTIC AREA |
86. 6.83 ARGENTINA MARKET ANALYSIS BY FORMULATION TYPE |
87. 6.84 ARGENTINA MARKET ANALYSIS BY END USER |
88. 6.85 ARGENTINA MARKET ANALYSIS BY INGREDIENT TYPE |
89. 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY THERAPEUTIC AREA |
90. 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY FORMULATION TYPE |
91. 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY END USER |
92. 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY INGREDIENT TYPE |
93. 6.90 MEA MARKET ANALYSIS |
94. 6.91 GCC COUNTRIES MARKET ANALYSIS BY THERAPEUTIC AREA |
95. 6.92 GCC COUNTRIES MARKET ANALYSIS BY FORMULATION TYPE |
96. 6.93 GCC COUNTRIES MARKET ANALYSIS BY END USER |
97. 6.94 GCC COUNTRIES MARKET ANALYSIS BY INGREDIENT TYPE |
98. 6.95 SOUTH AFRICA MARKET ANALYSIS BY THERAPEUTIC AREA |
99. 6.96 SOUTH AFRICA MARKET ANALYSIS BY FORMULATION TYPE |
100. 6.97 SOUTH AFRICA MARKET ANALYSIS BY END USER |
101. 6.98 SOUTH AFRICA MARKET ANALYSIS BY INGREDIENT TYPE |
102. 6.99 REST OF MEA MARKET ANALYSIS BY THERAPEUTIC AREA |
103. 6.100 REST OF MEA MARKET ANALYSIS BY FORMULATION TYPE |
104. 6.101 REST OF MEA MARKET ANALYSIS BY END USER |
105. 6.102 REST OF MEA MARKET ANALYSIS BY INGREDIENT TYPE |
106. 6.103 KEY BUYING CRITERIA OF HEALTHCARE |
107. 6.104 RESEARCH PROCESS OF MRFR |
108. 6.105 DRO ANALYSIS OF HEALTHCARE |
109. 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE |
110. 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE |
111. 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE |
112. 6.109 HEALTHCARE, BY THERAPEUTIC AREA, 2024 (% SHARE) |
113. 6.110 HEALTHCARE, BY THERAPEUTIC AREA, 2024 TO 2035 (USD Billion) |
114. 6.111 HEALTHCARE, BY FORMULATION TYPE, 2024 (% SHARE) |
115. 6.112 HEALTHCARE, BY FORMULATION TYPE, 2024 TO 2035 (USD Billion) |
116. 6.113 HEALTHCARE, BY END USER, 2024 (% SHARE) |
117. 6.114 HEALTHCARE, BY END USER, 2024 TO 2035 (USD Billion) |
118. 6.115 HEALTHCARE, BY INGREDIENT TYPE, 2024 (% SHARE) |
119. 6.116 HEALTHCARE, BY INGREDIENT TYPE, 2024 TO 2035 (USD Billion) |
120. 6.117 BENCHMARKING OF MAJOR COMPETITORS 7 LIST OF TABLES |
121. 7.1 LIST OF ASSUMPTIONS | |
  1. 7.1.1 |
122. 7.2 North America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.2.1 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  2. 7.2.2 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
  3. 7.2.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.2.4 BY INGREDIENT TYPE, 2025-2035 (USD Billion) |
123. 7.3 US MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.3.1 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  2. 7.3.2 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
  3. 7.3.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.3.4 BY INGREDIENT TYPE, 2025-2035 (USD Billion) |
124. 7.4 Canada MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.4.1 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  2. 7.4.2 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
  3. 7.4.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.4.4 BY INGREDIENT TYPE, 2025-2035 (USD Billion) |
125. 7.5 Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.5.1 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  2. 7.5.2 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
  3. 7.5.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.5.4 BY INGREDIENT TYPE, 2025-2035 (USD Billion) |
126. 7.6 Germany MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.6.1 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  2. 7.6.2 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
  3. 7.6.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.6.4 BY INGREDIENT TYPE, 2025-2035 (USD Billion) |
127. 7.7 UK MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.7.1 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  2. 7.7.2 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
  3. 7.7.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.7.4 BY INGREDIENT TYPE, 2025-2035 (USD Billion) |
128. 7.8 France MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.8.1 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  2. 7.8.2 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
  3. 7.8.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.8.4 BY INGREDIENT TYPE, 2025-2035 (USD Billion) |
129. 7.9 Russia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.9.1 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  2. 7.9.2 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
  3. 7.9.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.9.4 BY INGREDIENT TYPE, 2025-2035 (USD Billion) |
130. 7.10 Italy MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.10.1 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  2. 7.10.2 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
  3. 7.10.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.10.4 BY INGREDIENT TYPE, 2025-2035 (USD Billion) |
131. 7.11 Spain MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.11.1 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  2. 7.11.2 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
  3. 7.11.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.11.4 BY INGREDIENT TYPE, 2025-2035 (USD Billion) |
132. 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.12.1 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  2. 7.12.2 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
  3. 7.12.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.12.4 BY INGREDIENT TYPE, 2025-2035 (USD Billion) |
133. 7.13 APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.13.1 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  2. 7.13.2 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
  3. 7.13.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.13.4 BY INGREDIENT TYPE, 2025-2035 (USD Billion) |
134. 7.14 China MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.14.1 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  2. 7.14.2 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
  3. 7.14.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.14.4 BY INGREDIENT TYPE, 2025-2035 (USD Billion) |
135. 7.15 India MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.15.1 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  2. 7.15.2 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
  3. 7.15.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.15.4 BY INGREDIENT TYPE, 2025-2035 (USD Billion) |
136. 7.16 Japan MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.16.1 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  2. 7.16.2 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
  3. 7.16.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.16.4 BY INGREDIENT TYPE, 2025-2035 (USD Billion) |
137. 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.17.1 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  2. 7.17.2 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
  3. 7.17.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.17.4 BY INGREDIENT TYPE, 2025-2035 (USD Billion) |
138. 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.18.1 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  2. 7.18.2 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
  3. 7.18.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.18.4 BY INGREDIENT TYPE, 2025-2035 (USD Billion) |
139. 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.19.1 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  2. 7.19.2 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
  3. 7.19.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.19.4 BY INGREDIENT TYPE, 2025-2035 (USD Billion) |
140. 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.20.1 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  2. 7.20.2 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
  3. 7.20.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.20.4 BY INGREDIENT TYPE, 2025-2035 (USD Billion) |
141. 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.21.1 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  2. 7.21.2 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
  3. 7.21.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.21.4 BY INGREDIENT TYPE, 2025-2035 (USD Billion) |
142. 7.22 South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.22.1 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  2. 7.22.2 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
  3. 7.22.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.22.4 BY INGREDIENT TYPE, 2025-2035 (USD Billion) |
143. 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.23.1 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  2. 7.23.2 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
  3. 7.23.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.23.4 BY INGREDIENT TYPE, 2025-2035 (USD Billion) |
144. 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.24.1 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  2. 7.24.2 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
  3. 7.24.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.24.4 BY INGREDIENT TYPE, 2025-2035 (USD Billion) |
145. 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.25.1 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  2. 7.25.2 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
  3. 7.25.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.25.4 BY INGREDIENT TYPE, 2025-2035 (USD Billion) |
146. 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.26.1 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  2. 7.26.2 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
  3. 7.26.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.26.4 BY INGREDIENT TYPE, 2025-2035 (USD Billion) |
147. 7.27 MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.27.1 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  2. 7.27.2 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
  3. 7.27.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.27.4 BY INGREDIENT TYPE, 2025-2035 (USD Billion) |
148. 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.28.1 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  2. 7.28.2 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
  3. 7.28.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.28.4 BY INGREDIENT TYPE, 2025-2035 (USD Billion) |
149. 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.29.1 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  2. 7.29.2 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
  3. 7.29.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.29.4 BY INGREDIENT TYPE, 2025-2035 (USD Billion) |
150. 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST | |
  1. 7.30.1 BY THERAPEUTIC AREA, 2025-2035 (USD Billion) | |
  2. 7.30.2 BY FORMULATION TYPE, 2025-2035 (USD Billion) | |
  3. 7.30.3 BY END USER, 2025-2035 (USD Billion) | |
  4. 7.30.4 BY INGREDIENT TYPE, 2025-2035 (USD Billion) |
151. 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL | |
  1. 7.31.1 |
152. 7.32 ACQUISITION/PARTNERSHIP | |

Certified Researchers

Customize Report

Compounded Pharmacy Market Segmentation

Compounded Pharmacy Market By Therapeutic Area (USD Billion, 2025-2035)

Pain Management
Hormonal Therapies
Pediatric Care
Dermatology
Ophthalmology

Compounded Pharmacy Market By Formulation Type (USD Billion, 2025-2035)

Topical
Oral
Injectable
Nasal
Transdermal

Compounded Pharmacy Market By End User (USD Billion, 2025-2035)

Hospitals
Pharmacies
Home Compounded Pharmacy Market
Long-Term Care Facilities
Research Laboratories

Compounded Pharmacy Market By Ingredient Type (USD Billion, 2025-2035)

Active Pharmaceutical Ingredients
Excipients
Preservatives
Flavoring Agents
Coloring Agents

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”